Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00701636 · ClinicalTrials.gov registry record · Phase 3
Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery
A Phase 3 study, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT00701636 is a Phase 3 study that has completed, run by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. The registered enrollment target is 30 participants.
The verdict
NCT00701636, a Phase 3 study, has completed, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
This investigation is a prospective, open-label pharmacokinetic study of daptomycin prophylaxis in patients undergoing coronary artery bypass graft surgery without valvular replacement.
Interventions
- DRUG daptomycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-07 |
| Est. Completion | 2010-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00701636
The ClinicalTrials.gov registry entry for NCT00701636 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, which has 55 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which daptomycin is the first listed.
NCT00701636 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00701636 about?
NCT00701636 is a clinical study titled "Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery". This investigation is a prospective, open-label pharmacokinetic study of daptomycin prophylaxis in patients undergoing coronary artery bypass graft surgery without valvular replacement.
What is the current status of trial NCT00701636?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2008-07. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00701636?
The interventions under investigation include: daptomycin (DRUG).
Who is sponsoring clinical trial NCT00701636?
This trial is sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, which has 55 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.